Compare GEMI & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEMI | XNCR |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2025 | 2013 |
| Metric | GEMI | XNCR |
|---|---|---|
| Price | $11.35 | $16.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $24.25 | $22.44 |
| AVG Volume (30 Days) | ★ 2.1M | 702.8K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $162,529,000.00 | $150,132,000.00 |
| Revenue This Year | $24.88 | $18.81 |
| Revenue Next Year | $94.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 65.61 | 38.16 |
| 52 Week Low | $9.67 | $6.92 |
| 52 Week High | $45.89 | $26.59 |
| Indicator | GEMI | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 57.11 |
| Support Level | N/A | $15.69 |
| Resistance Level | N/A | $18.69 |
| Average True Range (ATR) | 0.00 | 0.99 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 48.04 |
Gemini Space Station Inc is engaged on unlocking the next era of financial, creative, and personal freedom. It envisions a future where crypto will redesign the global financial system, the internet, and money in a way that provides greater choice, independence, and opportunity for all. As a trusted bridge between the traditional financial system and the emerging crypto economy, It is providing access for individuals and institutions to a decentralized future that is more open, fair, and secure. Its core exchange product has expanded over time to become a comprehensive platform for its users to engage with the crypto economy, including a derivatives exchange, staking services, an over-the-counter (OTC) trading desk, institutional-grade custody, and others.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.